Drug Class Detail

Drug Class VEGF Antibody

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
HD105 DLL4 Antibody 6 VEGF Antibody 10 HD105 is a bi-specific antibody that targets VEGF and DLL4, resulting in decreased ligand-receptor binding and potentially leading to reduced tumor progression (PMID: 27049350).
FKB238 VEGF Antibody 10 FKB238 is a biosimilar to Avastin (bevacizumab), which is a VEGFA targeted antibody (J Clin Oncol 35, 2017 (suppl; abstr e14007)).
ABT-165 DLL4 Antibody 6 VEGF Antibody 10 ABT-165 is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which results in tumor growth inhibition (PMID: 29592882).
Ranibizumab Lucentis rhuFab V2 VEGF Antibody 10 Ranibizumab is a monoclonal antibody that binds VEGF-A, preventing receptor binding and potentially resulting in decreased growth of blood vessels (NCI Drug Dictionary).
PTC299 VEGF Antibody 10 PTC299 inhibits dihydroorotate dehydrogenase (DHODH), thereby preventing pyrimidine nucleotide synthesis and downstream VEGFA production, resulting in inhibition of cell migration and proliferation (PMID: 30352802).
BI 695502 VEGF Antibody 10 BI 695502 is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (PMID: 28651442).
Bevacizumab-awwb Mvasi ABP 215 VEGF Antibody 10 Mvasi (bevacizumab-awwb) is a biosimilar to the anti-VEGF antibody Avastin (bevacizumab), which binds to and inhibits VEGF, resulting in decreased tumor growth and angiogenesis (Ann Oncol (2014) 25 (suppl 4): iv163; Abstract 489P). Mvasi (bevacizumab-awwb) is FDA approved for patients with colorectal cancer, non-small cell lung carcinoma, glioblastoma, renal cell carcinoma, and cervical cancer (FDA.gov).
Aflibercept Zaltrap AVE 0005|Eylea VEGF Antibody 10 VEGFR Inhibitor (Pan) 30 Zaltrap (aflibercept) is comprised of human IgG fused to the extracellular domains of VEGFR1 and VEGFR2, which binds VEGF to inhibit tumor angiogenesis and metastasis (NCI Drug Dictionary). Zaltrap (aflibercept) is FDA approved in patients with metastatic colorectal cancer (FDA.gov).
Bevacizumab Avastin VEGF Antibody 10 VEGFR Inhibitor (Pan) 30 Avastin (bevacizumab) is a monoclonal antibody that binds VEGF and inhibits binding to VEGFR, potentially resulting in decreased tumor growth (PMID: 15136787). Avastin (bevacizumab) is FDA approved for use in colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical carcinoma, and ovarian cancer, and in combination with carboplatin and paclitaxel in epithelial ovarian, fallopian tube, or primary peritoneal cancer (FDA.gov).
OMP-305B83 Navicixizumab DLL4 Antibody 6 VEGF Antibody 10 Navicixizumab (OMP-305B83) is a bispecific antibody that binds both DLL4 and VEGF, which inhibits NOTCH and VEGFR signaling and may prevent angiogenesis and tumor growth (NCI Drug Dictionary).
Molecular Profile Protein Effect Treatment Approaches